Lantern Pharma achieved significant clinical and regulatory milestones in Q3 2025, particularly with the successful Phase Ia trial of LP-184, which demonstrated a 48% clinical benefit rate in evaluable cancer patients.
- LP-184's Phase Ia trial met all primary endpoints, with notable tumor reductions in patients with specific DNA damage repair mutations.
- Starlight Therapeutics received favorable guidance from the FDA for its planned pediatric CNS cancer trial, combining LP-184 with spironolactone.
- Preliminary Phase II data from the LP-300 HARMONIC trial was presented, with a comprehensive update expected in December.
- Lantern is advancing LP-184 into targeted Phase Ib/II trials across four significant oncology indications, with a potential market exceeding $7 billion.
- The RADR AI platform demonstrated commercial readiness, with viable modules for licensing to biopharma partners.
Community Discussion